- Global Pharma News & Resources

Chronic Refractory Cough Treatment Market is projected to reach USD 17.1 billion by 2033, trailing a CAGR of 6.39%

The Chronic Refractory Cough Treatment Market is anticipated to be worth US$ 9.2 billion in 2023 and US$ 17.1 billion by 2033, growing at a CAGR of 6.39%.

The market for treatments for refractory chronic cough is driven by the rising prevalence of refractory chronic cough worldwide. The size of the market would increase, enabling pharmaceutical companies to enhance their market share, due to rising global healthcare spending and disease awareness. Modern techniques to treat or treat more effectively the sickness condition are the focus of the medicines currently in development.

The market for treating chronic refractory cough reached US$ 7 billion in 2018 and expanded at a CAGR of 5.62%. In order to relieve patients from cough hypersensitivity, healthcare businesses are investing in opiates and GABA (gamma-aminobutyric acid)-related substances. Opiates have powerful antitussive qualities and work as excellent cough suppressants to treat persistent, intractable cough. The ability of businesses to produce tramadol, an opioid medicine with a chemical structure comparable to that of codeine pharmaceuticals, is also growing.

Request Sample @

Since chronic cough causes increased body pain, companies in the Chronic refractory cough treatment market are increasing the availability of gabapentin and pregabalin, which are GABA-related compounds, and act as neuromodulators for the treatment of neuropathic pain and epilepsy. It has been found in placebo-controlled trials that; gabapentin is well-tolerated for the treatment of refractory chronic cough. Thus, leading to market expansion.

Considering these factors, the market for Chronic refractory cough treatment is projected to reach US$ 17.1 billion by end of the forecast period, while exhibiting a CAGR of 6.39%.

Which market will have the highest share according to the distribution channel?
Retail pharmacies rule the market and are fueling expansion.

With a predicted 55% market share, the retail pharmacy segment is predicted to rule the market. The ease accessibility and availability of these pharmacies is responsible for the growth. For instance, MedPlus has approximately 1650 shops, 1,350 of which are owned by the company directly, while the others are franchised. Customers choose these distribution channels because retailers provide discounts on large purchases, offer speedy delivery, and always have enough product stock, which is what propels the segment’s growth.

Ask An Analyst @

The market for treating chronic refractory cough may be severely lacking in approved medicines, which could impede growth. The accurate and prompt diagnosis of Chronic Refractory Cough is hampered by the lack of reliable biomarkers. These elements will prevent the market from growing.

Key Segments Profiled in the Chronic Refractory Cough Treatment Industry Survey

By Drug Class:

  • Antibiotics
  • Decongestants
  • Corticosteroids
  • Antihistamines
  • Acid Blockers
  • Others

By Route of administration:

  • Oral
  • Nasal
  • Parenteral
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Request Customization @

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries:
LinkedIn| Twitter| Blogs

Editor Details

Last Updated: 24-May-2023